Background:
Cabotegravir-rilpivirine (CAB-RPV), the first intramuscular injectable antiretroviral therapy (ART) for people with HIV, is associated with high compliance rates and patient satisfaction. Multiple studies demonstrate low rates of virologic failure (VF) and development of resistance, confirmed by real world analyses. Here we describe our experience with a higher rate of VF at an HIV clinic in Chicago, IL.
Methods:
We assessed baseline viral loads (VL) at time of switch in ART, clinic location for the injections and response after transitioning to CAB-RPV. VF was defined as two consecutive VL >200 copies/ml. Resistance mutations in patients with VF were recorded.
Results:
75 undetectable patients (UD, VL <40 copies/ml) were switched to CAB-RPV. 10 received their injections at an independent infusion center (IC) with trained injectors. 65 received injections at our clinic. Two of ten patients at IC and 1 of 65 patients at our clinic developed virologic failure (4%). One patient (pt1) had non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance (K103N), the second (pt2) had an M184V while a genotype failed for the third patient (pt3) at the time of diagnosis. Patients had lived with HIV for 23, 18 and 1 year, respectively, before switch and were lifelong nonsmokers. Pt1 was UD for 2 months and the other two were UD for >6 months prior to switch. All were on an integrase inhibitor (INI) based regimen. Body mass index (BMI) were 27, 35 and 28 respectively. The patients were UD for 6, 10 and 18 months respectively on CAB-RPV before VF. Genotypes at the time of VF revealed INI mutations in pt1: L74I, T97T/A, S147S/G, N155H, INI and NNRTI mutations in pt2: L74L/M, T97T/A, G140S, Q148H and K101E, E138K, I178L, Q207E and INI mutations in pt3: G140G/S, Q148Q/R. None had a missed or delayed dose of CAB-RPV. 1.5-inch needles were used in all three. The two IC patients raised concerns about irregular injection techniques. All three switched to a protease inhibitor-based regimen and were subsequently UD.
Conclusions:
While injectable ART are revolutionary in HIV care, clinicians should be aware of possible higher real-world failure rates due to nonstandard injection practices, smoking status, high BMI or unknown pre-existing resistance mutations. Ensuring appropriate training for injecting staff, use of longer needles and obtaining HIV-1 proviral DNA resistance assays may be considered prior to switching to CAB-RPV to further decrease the risk of VF.